The single small trial reported symptom improvement in approximately 60% of participants (pain reduction, fatigue improvement, better sleep), but without a placebo control or sham-injection group, attribution of benefit to the cell therapy versus natural fluctuation or expectancy is impossible. Real-world success rates remain unknown.
Only 1 completed trial and 0 actively recruiting trials are registered specifically for fibromyalgia cell therapy, reflecting the early, exploratory stage of this application. That single published study involved placental MSC infusion in a small cohort (n≈20–30) and reported modest improvements in pain scores (average 20–30% reduction on visual analogue pain scale) and some improvement in fatigue severity. Biochemical markers of inflammation (IL-6, TNF-α) showed trending reductions. No control arm was present, and long-term follow-up was not reported.
Suis-je un candidat? → · Fibromyalgia & Chronic Fatigue: full overview → · Coût Fibromyalgie et Syndrome de Fatigue Chronique → · Cost →
Médicalement examiné par l'équipe éditoriale de StemCellAtlas avec Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) de la clinique partenaire Stem Plus (Sofia), selon les directives ISSCR, FDA et EMA. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite